Apelin - a new protein-regulator in the cardiovascular system


Cite item

Full Text

Abstract

Apelin is an endogenic ligand of apelin (APJ) receptors widely expressed in human tissues. This protein is a peripheral vasodilator having a powerful positive inotropic action on myocardial contractility. This review describes mechanisms of interaction and apelin role in health and pathology.

References

  1. Lee D. K., Cheng R., Nguyen Tan T. et al. Characterization apelin, the ligand for the APJ receptor. J. Neurochem. 2000; 74 (1): 34-41.
  2. Badrinathan Chandrasekaran, Owais Dar, McDonagh Th. The role of apelin in cardiovascular function and heart failure. Eur. J. Heart Fail. 2008; 10: 725-732.
  3. Tatemoto K., Hosoya M., Habata Y. et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 1998; 251 (2): 471-476.
  4. O'Dowd B. F., Heiber M., Chan A. et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136 (1-2): 355- 360.
  5. Hosoya M., Kawamata Y., Fukusumi S. et al. Molecular and function characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem. 2000; 275 (28): 21061-21067.
  6. Lee D. K., Saldivia V. R., Nguyen T. et al. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 2005: 146 (1): 231-236.
  7. Kleinz M. J., Davenport A. P. Immunocytochemical localization of endogenous vasoactive peptide apelin to human vascular endocardial endothelial cells. Regul. Pept. 2004; 118 (3): 119-125.
  8. Falcao-Pires I., Leite-Moreira A. F. Apelin: a novel neurohumoral modulator of the Port cardiovascular system. Pathophysiologic impotence and potential use a therapeutic target. Rev. Cardiol. 2005; 24 (10): 1263-1276.
  9. Tatemoto K., Takayama K., Zou M. X. et al. The novel peptide apelin lowres blood pressure via a nitric oxide-dependent mechanism. Regul. Pept. 2001; 99 (2-3): 87-92.
  10. Cheng X., Cheng X. S., Pang C. C. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur. J. Pharmacol. 2003; 470 (3): 171-175.
  11. Charles C. J., Rademaker M. T., Richards A. M. Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep. J. Endocrinol. 2006; 189 (3): 701-710.
  12. Jia Y. X., Lu Z. E., Zhang J. et al. Apelin activates L-arginine/ nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 2007; 28 (10): 202-209.
  13. Hashimoto T., Kihara M., Ishida J. et al. Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2006; 26 (6): 1267- 1272.
  14. Zhong J. C., Huang D. Y., Liu G. F. et al. Effects of all-trans retinoic acid on orphan receptor APJ signaling in spontaneously hypertensive rats. Cardiovasc. Res. 2005; 65 (3): 743-750.
  15. Gurzu B., Petrescu В. С., Costuleanu M., Petrescu G. Interactions between apelin and Angiotensin II on rat portal vein. J. Renin Angiotensin Aldosterone Syst. 2006; 7 (4): 212-216.
  16. Szokodi I., Tavi P., Foldes G. et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ. Res. 2002; 91 (5): 434-440.
  17. Ashley E. A., Powers J., Chen M. et al. The endogenous peptide apelin potently improves cardiac contractility and reduce cardiac loading in vivo. Cardiovasc. Res. 2005; 65 (1): 73-82.
  18. Brailoiu G. C., Dun S. L., Yang J. et al. Apelin-immunoreactivity in the rat hypothalamus and pituitary. Neurosci. Lett. 2002; 327 (3): 193-197.
  19. Ishida J., Hashimoto T., Hashimoto Y. et al. Regulatory roles for APJ, a seven-Transmembrane receptor related to angiotensin - type 1 receptor in blood pressure in vivo. J. Biol. Chem. 2004; 279 (25): 26274-26279.
  20. Kuba K., Zhang L., Imai Y. et al. Impaired heart contractility in Apelin gene - deficient mice associated with aging and pressure overload. Circ. Res. 2007; 101 (4): 32-42.
  21. Vickers C., Hales P., Kaushik V. et al. Hydrolysis of biological peptides by human Angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 2002; 277 (17): 14838- 14843.
  22. Farkasfalvi K., Stagg M. A., Coppen S. R. et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem. Biophys. Res. Commun. 2007; 357 (4): 889-895.
  23. Zhang J., Ren C. X., Qi Y. F. et al. Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci. 2006; 79 (12): 1153- 1159.
  24. Sheikh A. Y., Chun H. J., Glassford A. J. et al. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am. J. Physiol. Heart Circ. Physiol. 2008; 294 (1): 88-98.
  25. Simpkin J. C., Yellon D. M., Davidson S. M. et al. Apelin-36 exhibit direct cardioprotective activity against ischemia reperfusion injury. Basic Res. Cardiol. 2007; 102 (6): 518-528.
  26. Chong K. S., Gardner R. S., Morton J. J. et al. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur. J. Heart Fail. 2006; 8 (4): 355-360.
  27. Chen M. M., Ashley E. A., Deng D. X. et al. Novel role for the potent endogenous inotrope Apelin in human cardiac dysfunction. Circulation 2003; 108 (12): 1432-1439.
  28. Goetze J. P., Rehfeld J. F., Carlsen J. et al. Apelin : a new plasma marker of cardiopulmonary disease. Regul. Pept. 2006; 133 (1-3): 134-138.
  29. Miettinen K. H., Magga J., Vuolteeaho O. et al. Utility of plasma apelin and jther indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul. Pept. 2007; 140 (3): 178-184.
  30. Hashimoto T., Kihara M., Imai N. et al. Requirement of apelin - apelin receptor system for oxidative stress - linked atherosclerosis. Am. J. Pathol. 2007; 171 (5): 1705-1712.
  31. Tasci I., Doru T., Naharci I. et al. Plasma apelin is lower in patients with elevated LDL- cholesterol. Exp. Clin. Endocrinol. Diabet. 2007; 115 (7): 428-432.
  32. Maiyszko J., Maiyszko J. S., Kozminski P., Mysliwiec M. Apelin and cardiac function in hemodialyzed patients: possible relations? Am. J. Nephrol. 2006; 26 (2): 121-126.
  33. Codognotto M., Piccoli A., Zaninotto M. et al. Evidence for decreased circulating apelin beyond heart involvement in uremic cardiomyopathy. Am. J. Nephrol. 2007; 27 (1): 1-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies